Yinping Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yinping Lin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Changhui Wang
Department of Respiratory Medicine, Shanghai 10th People’s Hospital, Tongji University, Shanghai, China
3 shared publicationsMing Li
Department of Respiratory Medicine, Shanghai 10th People’s Hospital, Tongji University, Shanghai, China
3 shared publicationsShenjun Zhang
Institute of Biochemistry and Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publicationsLiang Wu
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
2 shared publicationsNing Wu
Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China
2 shared publicationsWeiwei Zhang
Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
1 shared publication
Latest Publications
- RetractionOpen Access
- 23 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
Retraction Note: Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3
- 23 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
RetractionOpen AccessRetraction Note: Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3
- RetractedOpen Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (10) , 1795-1800
PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer
Purpose: Long noncoding RNAs (lncRNAs) have been demonstrated as effective markers for cancer detection and prognosis prediction. The aim of this study was to determine whether tissue PART1 could be used as a biomarker for prognosis prediction of non-small cell lung cancer (NSCLC).
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (10) , 1795-1800
RetractedOpen AccessPART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer
Purpose: Long noncoding RNAs (lncRNAs) have been demonstrated as effective markers for cancer detection and prognosis prediction. The aim of this study was to determine whether tissue PART1 could be used as a biomarker for prognosis prediction of non-small cell lung cancer (NSCLC).
- RetractedOpen Access
- 14 March 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 23100
RETRACTED ARTICLE: Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3
Dysregulation of miRNAs is reported to be involved in the invasion and metastasis of lung cancer. Previous studies showed that low serum miR-499 expression was associated with advanced TNM stage and poor prognosis. The present study is carried out to evaluate the biological functions of miR-499-5p in lung cancer. We demonstrated that miR-499-5p was significantly reduced in NSCLC tissues and correlated with poor clinical outcomes. Overexpression of miR-499-5p inhibited cell proliferation and induced apoptosis in vitro and in vivo. Furthermore, miR-499-5p overexpression also inhibited NSCLC metastasis in vitro and in vivo. Using bioinformatics tools, we identified VAV3 as a candidate target of miR-499-5p, and demonstrated that restoration of miR-499-5p expression in NSCLC cells downregulated VAV3 expression while inhibition of miR-499-5p upregulated VAV3 expression. Luciferase reporter assays showed that miR-499-5p targeted 3′-UTR of VAV3. Moreover, cancer growth, proliferation and metastasis were decreased and apoptosis was increased after VAV3 blockage induced by miR-499-5p overexpression. We conclude that miR-499-5p functions as a tumor suppressor by targeting VAV3. This finding may provide a therapeutic approach for future treatment of NSCLC.
- 14 March 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 23100
RetractedOpen AccessRETRACTED ARTICLE: Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3
Dysregulation of miRNAs is reported to be involved in the invasion and metastasis of lung cancer. Previous studies showed that low serum miR-499 expression was associated with advanced TNM stage and poor prognosis. The present study is carried out to evaluate the biological functions of miR-499-5p in lung cancer. We demonstrated that miR-499-5p was significantly reduced in NSCLC tissues and correlated with poor clinical outcomes. Overexpression of miR-499-5p inhibited cell proliferation and induced apoptosis in vitro and in vivo. Furthermore, miR-499-5p overexpression also inhibited NSCLC metastasis in vitro and in vivo. Using bioinformatics tools, we identified VAV3 as a candidate target of miR-499-5p, and demonstrated that restoration of miR-499-5p expression in NSCLC cells downregulated VAV3 expression while inhibition of miR-499-5p upregulated VAV3 expression. Luciferase reporter assays showed that miR-499-5p targeted 3′-UTR of VAV3. Moreover, cancer growth, proliferation and metastasis were decreased and apoptosis was increased after VAV3 blockage induced by miR-499-5p overexpression. We conclude that miR-499-5p functions as a tumor suppressor by targeting VAV3. This finding may provide a therapeutic approach for future treatment of NSCLC.